KeyBanc raised the firm’s price target on Certara (CERT) to $18 from $15 and keeps an Overweight rating on the shares. . Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara’s Hold Rating: Balancing Short-term Resilience with Long-term Regulatory Opportunities
- Certara’s Balanced Outlook: Hold Rating Amid Mixed Signals of Growth and Risk
- Certara launches Non-Animal Navigator solution
- Certara reaffirms FY25 revenue guidance $415M-$425M, consensus $419.97M
- Certara continues strategic evaluation of regulatory services business